Peer Review History
| Original SubmissionOctober 6, 2021 |
|---|
|
PONE-D-21-31986Hour-1 bundle adherence was associated with reduction of in-hospital mortality among patients with sepsis in JapanPLOS ONE Dear Dr. Abe, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Dec 24 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Ashham Mansur, MD, PhD Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Thank you for stating the following financial disclosure: [The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.] At this time, please address the following queries: a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution. b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.” c) If any authors received a salary from any of your funders, please state which authors and which funders. d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.” Please include your amended statements within your cover letter; we will change the online submission form on your behalf. 3. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. In your revised cover letter, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. We will update your Data Availability statement on your behalf to reflect the information you provide. Additional Editor Comments: The reviewers have raised major concerns regarding to the relatively small number of patients in relation to the number pf the involved centers. you need to adress this major issue adequately and make corrdctions to the conclusions respectively. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Partly Reviewer #3: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: I Don't Know Reviewer #3: I Don't Know ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: No Reviewer #3: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Thank you for the opportunity to review this manuscript. This was a prospective, multi-center, observational study to validate the effectiveness of hour-1 bundle in Japanese patients with sepsis. They concluded that the adherence of hour-1 bundle was associated with decreased mortality risk, and the collection of blood culture and administration of antibiotics within 1 hour was independently associated with mortality risk in septic patients. I had several comments that the authors need to address: 1. The definition of hour-1 bundle adherence: the authors mentioned that "if a component of the bundle was not applicable, we treated achievement of the other components as completion of the bundle". I have concerns of that the authors mixed the non-shock and shock patients in this study (although the guideline did it so, and growing evidence suggested that these two groups should be treated differently). For example, 79 of 178 patients had no vasopressor administration (Table S1) and they were presumed to have low disease severity and mortality risk. What were the distribution of these non-shock patients in the adherence and non-adherence groups? They may significantly influence the study outcomes. I suggest the authors to perform subgroup analysis (shock: adherence vs.non-adherence, non-shock: adherence vs. non-adherence) in outcome analysis. 2. Since this study was conducted in multiple ICUs in Japanese hospitals, these patients were presumed to admit in ICUs, but they had relative low proportion of vasopressor administration and mechanical ventilator use. They also had very low CCI score. 3. Please clarify the origin of vital signs and laboratory results of each patient? from initial time of ICU admission? from initial hospital admission? from the time of sepsis recognition? 4. It's surprising that the proportion of antibiotics administration within one hour was lower than vasopressor administration (Table S1). Since the authors identifies the antibiotics administration as the independent factor associated with mortality risk, they may want to address more on this issue. 5. Similarly, the authors mentioned that they applied "multidisciplinary methods" to promote the adherence of hour-1 bundle in patients with sepsis. They should address more how they did it as the issue of quality improvement. 6. The recruitment period is different: in the design and setting "from July 2019 to August 2020." In the figure 1 "from July 2019 to December 2019" So the recruitment period is 13 or 6 months? Reviewer #2: I read with interest the manuscript of Umemura et al. entitled “Hour-1 bundle adherence was associated with reduction of in-hospital mortality among patients with sepsis in Japan”. In the present study the authors aimed to evaluate the effect of hour-1 bundle completion on clinical outcomes in sepsis. They showed an association between completion of the hour-1 bundle and lower in-hospital mortality in an observational multicenter study of 178 prospectively enrolled patients with sepsis. The study’s conclusions are presented in an appropriate fashion and are supported by the data. The studies sample size of 178 individuals appears low in order to draw the presented conclusions, especially considering that 17 centers were involved into the study. The article is presented in an intelligible fashion and is written in standard English. However, the following comments/questions need to be addressed by the authors: 1. Introduction: “A recent study did not show an association between completion of the hour-1 bundle components within 1 hour and lower mortality, whereas they did show an association between care completed within 3 hours and lower mortality [9].” Reference (9) refers to patients with septic shock and not patients with sepsis. The authors need to clarify that in the introduction or reference appropriate other studies. 2. The authors should provide a clear hypothesis at the end of the introduction based on clinical adjudication or existing research in the field. 3. How was the sample size of n=178 determined? The authors should provide a power calculation in order to verify that the sample size of n=178 is appropriate to show the study’s results at sufficient statistical power. 4. The authors state that 178 patients were enrolled into the study. 89 of the patients received bundle-adherent care (50%). However, it is stated in the results section that “the rate of completion of all components within 1 hour was 50.3%”. This is confusing. How do the authors explain 50.3% in table S1, while it should be 50%? Are the numbers correct? 5. The authors should clarify, if and how the performed multivariate analysis adjusts for the differences between the two groups at baseline (blood temperature and mechanical ventilation use). 6. “A systematic review of seven observational studies in the Japanese clinical practice guidelines for management of sepsis and septic shock 2020 showed no significant difference in outcomes with administration of antibiotic within 1 hour compared to later. “ The authors need to provide a reference for this in the discussion section. Reviewer #3: Please get a native English speaker to correct the language in the manuscript. The lanugage is not up to the standard. It might be reasonable to include the following in the limitation: The study did not anayse the reasons for non adherence. It would be better if a graph/ table could show the time time period taken to complete the bundle in the non adherent group. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
Hour-1 bundle adherence was associated with reduction of in-hospital mortality among patients with sepsis in Japan PONE-D-21-31986R1 Dear Dr. Abe, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Ashham Mansur, MD, PhD Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: (No Response) Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: (No Response) Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: (No Response) Reviewer #2: No ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: (No Response) Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: (No Response) Reviewer #2: Thank you for the provided point by point review. All mentioned concerns have been addressed sufficiently. I recommend to accept the manuscript in the current version. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No |
| Formally Accepted |
|
PONE-D-21-31986R1 Hour-1 bundle adherence was associated with reduction of in-hospital mortality among patients with sepsis in Japan Dear Dr. Abe: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Ashham Mansur Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .